This article is for informational and educational purposes only and does not constitute medical advice. Cortagen is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Cortagen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Pro (AEDP) and a molecular weight of approximately 430 Da. It belongs to the peptide bioregulator class developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, originally derived from research on bovine cerebral cortex tissue extracts. The compound is proposed to function as a cortex-specific peptide bioregulator with the capacity to modulate gene expression in cortical neurons, with reported preclinical associations with neuroprotective effects and chromatin activity modulation in neuronal preparations. The proposed mechanism is framed within the Khavinson bioregulator hypothesis that short peptides derived from target organ extracts regulate gene transcription through complementary interactions with promoter DNA sequences. As with other members of this compound class, the published evidence base is largely confined to the originating research group, independent replication by external laboratories has not been widely reported, and no regulatory authority has approved Cortagen for any clinical indication.
1. Background
1.1 The Peptide Bioregulator Concept
Cortagen belongs to the Khavinson peptide bioregulator class — a series of short synthetic peptides proposed to regulate gene expression in a tissue-specific manner by interacting with promoter regions of DNA. The theoretical framework, developed beginning in the Soviet Union in the 1970s and continuing through the post-Soviet Russian scientific program, holds that short peptides derived from organ extracts carry sequence-specific information that modulates transcription in the corresponding target tissue. For a broader review of the bioregulator class and its methodological context, see the companion articles on Epitalon (AEDG) and Pinealon (EDR).
Cortagen was developed as a derivative of a peptide fraction isolated from bovine cerebral cortex tissue. Its four-amino-acid sequence Ala-Glu-Asp-Pro shares the Ala-Glu-Asp N-terminal tripeptide with several other members of the class, including Epitalon (Ala-Glu-Asp-Gly), Cardiogen (Ala-Glu-Asp-Arg), and Bronchogen (Ala-Glu-Asp-Leu). The C-terminal proline residue distinguishes Cortagen from all other members of this AED- series: proline is a cyclic imino acid whose nitrogen is incorporated into a five-membered pyrrolidine ring, which introduces conformational constraints on the peptide backbone that are absent in the flexible glycine, leucine, or arginine C-termini of the related compounds.
1.2 Cortical Neuron Biology and the Rationale for Neural Bioregulation
The cerebral cortex is the seat of higher cognitive function, integrating sensory input, directing motor output, and supporting complex processes including memory, language, and executive control. Its principal cellular constituents — cortical neurons — are among the most metabolically demanding and long-lived cells in the body. Cortical projection neurons established during embryonic development are largely maintained throughout life in humans, as adult cortical neurogenesis is either absent or extremely limited compared with regions such as the hippocampal dentate gyrus [3]. This permanent post-mitotic status means that cortical neuron loss from aging, ischemia, neurodegeneration, or traumatic injury is essentially irreversible.
The progressive loss and dysfunction of cortical neurons underlie the cognitive decline associated with normal aging as well as neurodegenerative conditions including Alzheimer’s disease, frontotemporal dementia, and vascular dementia. A major research challenge is identifying compounds that support cortical neuron survival and function, delay age-associated transcriptional and epigenetic changes, or protect neurons against ischemic and oxidative stress. The Khavinson group’s rationale for developing a cortex-targeted bioregulator was grounded in the hypothesis that a peptide derived from cortical tissue might restore or support the gene expression patterns associated with healthy cortical neuron function.
2. Molecular Structure
| Property | Value |
|---|---|
| Full name | Cortagen |
| Sequence (single-letter) | AEDP |
| Sequence (full names) | Ala-Glu-Asp-Pro |
| Molecular weight | ~430 Da |
| Molecular formula | C ₁₇H ₂₆N ₄O ₉ |
| Peptide length | 4 amino acids (tetrapeptide) |
| Net charge (physiological pH) | −2 (two acidic residues at positions 2–3; proline and alanine uncharged) |
| C-terminal residue note | Proline (Pro) is a cyclic imino acid; its nitrogen forms part of a pyrrolidine ring, constraining backbone conformation |
| Origin | Synthetic; sequence derived from bovine cerebral cortex extract research |
| Proposed primary target | Cortical neuronal gene promoter regions (proposed); cerebral cortex tissue-specific transcription |
| Related compounds | Epitalon (AEDG), Cardiogen (AEDR), Bronchogen (AEDL) — all share Ala-Glu-Asp N-terminal tripeptide |
The proline residue at position 4 is the defining structural feature that distinguishes Cortagen from all other AED- bioregulators. Proline’s cyclic side chain connects back to its own backbone nitrogen, forming a five-membered pyrrolidine ring that eliminates the normal N-H group at this position and introduces a fixed dihedral angle in the peptide backbone. This rigidity can restrict the conformational space available to the full AEDP tetrapeptide relative to sequences terminating in flexible residues like glycine (AEDG) or leucine (AEDL). Within the Khavinson framework, proline’s conformational constraint has been proposed as relevant to cortex-specific promoter recognition, though the structural basis for this claim has not been validated by independent biophysical experiments.
3. Proposed Mechanisms of Action
4. Key Research Findings
4.1 In Vitro Cortical Cell Studies
The primary in vitro evidence base for Cortagen centers on studies using cortical neuron cultures and neural cell preparations. The Khavinson group has reported that AEDP treatment in these systems is associated with changes in markers of neuronal viability, gene expression profiles relevant to cortical neuron function, and chromatin activity in neuronal preparations [1]. These in vitro observations are presented within the theoretical framework of the Khavinson bioregulator class, and the proposed neuroprotective and chromatin-modulatory effects form the mechanistic basis for the compound’s research interest.
As with other members of the Khavinson bioregulator class, the in vitro Cortagen literature originates predominantly from a single research group using methods developed within that group. Contemporary neuroscience employs experimental systems — including human-derived induced pluripotent stem cell (iPSC) cortical neurons, three-dimensional cortical organoids, and single-nucleus transcriptomic profiling — that would permit more rigorous investigation of the proposed effects. Replication using these methods by independent laboratories has not been reported.
4.2 Animal Neural Models
Animal model studies from the Khavinson group have examined Cortagen in experimental preparations assessing cortical function and neural tissue integrity, including aged rodent models and experimental cerebral ischemia preparations. Reported outcomes have included histological assessments of cortical tissue, measurements of neuronal marker expression, and functional indices of nervous system performance in treated versus control animals [1]. As with the cardiac and bronchial bioregulators, these animal data are subject to the single-group limitation that characterizes the broader Khavinson bioregulator literature.
Rodent models of cortical aging and ischemia differ from the pathophysiology of human neurodegenerative and cerebrovascular disease in important ways, including differences in brain size, neurovascular anatomy, genetic background, and the cellular mechanisms of cortical aging. The predictive value of rodent cortical model results for human cognitive outcomes is therefore limited.
Schematic representation of evidence depth at each research stage. Bar lengths are qualitative, not derived from a numerical index. Independent replication in each category is absent or minimal as of the review date.
4.3 Published Human Data
Published human data relevant to Cortagen are very limited. No peer-reviewed, randomized, placebo-controlled trial of Cortagen in human subjects has been identified as of the review date. The Khavinson group has reported observational data encompassing multiple bioregulator peptides in clinical populations, but controlled trials with Cortagen as the primary intervention and cortical or cognitive endpoints as pre-registered primary outcomes have not been identified [2].
The absence of controlled human trial data means that no assessment of safety, tolerability, blood-brain barrier penetration, pharmacokinetics, or cortical efficacy in human subjects can be drawn from the published evidence. Human cortical and cognitive endpoints are among the most difficult to measure rigorously, requiring large, long-duration randomized trials with validated neuropsychological and neuroimaging endpoints — a methodological standard that has not been applied to Cortagen.
5. Evidence Status
| Proposed Effect | Current Status | Evidence Level |
|---|---|---|
| Cortical neuron gene expression modulation | Reported in vitro by Khavinson group; no independent replication published | Limited |
| Neuroprotective activity (in vitro) | In vitro observations from originating group; specific targets not characterized | Limited |
| Chromatin modulation in neurons | Proposed from Khavinson group; no independent epigenomics validation | Limited |
| Neuroprotection in animal models | Animal model data from Khavinson group; single group; not independently replicated | Limited |
| Human cortical or cognitive outcomes | No controlled trials identified; no RCT data | Not Established |
| Blood-brain barrier penetration | Not characterized in published pharmacokinetic studies | Not Established |
| Sequence-specific promoter binding (AEDP) | Computational modeling only; no independent structural validation | Limited |
What We Still Don’t Know
- Whether cortical neuron gene expression effects are reproducible by independent investigators: All published observations of Cortagen’s effects on neuronal gene expression and viability originate from the Khavinson group. Replication using contemporary tools — including iPSC-derived cortical neurons, single-nucleus RNA sequencing, and ATAC-seq for chromatin accessibility — by independent laboratories is necessary to validate these claims.
- Whether AEDP crosses the blood-brain barrier in sufficient quantities: The blood-brain barrier is a highly selective endothelial and glial barrier that restricts the entry of most polar, water-soluble molecules from systemic circulation into brain parenchyma. For a tetrapeptide of ~430 Da with two negatively charged side chains, passive diffusion across the BBB is expected to be minimal, and active transport mechanisms for AEDP have not been identified or characterized in published pharmacokinetic studies.
- Whether adult cortical neurogenesis is relevant to Cortagen’s proposed effects: Unlike the hippocampal dentate gyrus, the adult human cerebral cortex does not undergo meaningful neurogenesis. Cortagen’s proposed neuroprotective effects therefore cannot invoke a regenerative mechanism; they would depend on protecting existing post-mitotic neurons, a conceptually distinct and arguably less tractable target.
- The molecular basis for proline-dependent cortical tissue selectivity: Within the AED- bioregulator series, the C-terminal proline is proposed to confer cortex specificity. The conformational constraints proline imposes on the AEDP backbone are structurally distinct from other members, but whether this translates to differential promoter-binding selectivity or differential tissue distribution has not been demonstrated in independent experiments.
- Relevance to human neurodegenerative disease: The conditions of greatest clinical relevance for a cortical neuroprotective compound — Alzheimer’s disease, frontotemporal dementia, vascular cognitive impairment — are multifactorial and involve mechanisms (amyloid aggregation, tau pathology, neuroinflammation, synapse loss) that are not addressed in the preclinical Cortagen literature.
6. Limitations of Current Research
References
- Khavinson VKh, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Basel: Karger; 2005. Monograph covering the peptide bioregulator class including cortical tissue bioregulator research and in vitro neuronal data.
- Anisimov VN, Khavinson VK. “Peptide bioregulation of aging: results and prospects.” Biogerontology. 2010;11(2):139–149. doi:10.1007/s10522-009-9249-8
- Spalding KL, Bhardwaj RD, Buchholz BA, Druid H, Frisén J. “Retrospective birth dating of cells in humans.” Cell. 2005;122(1):133–143. doi:10.1016/j.cell.2005.04.028 [Background reference establishing the post-mitotic permanence of cortical neurons in adult humans.]
- Pardridge WM. “Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.” Expert Opinion on Drug Delivery. 2015;12(2):207–222. doi:10.1517/17425247.2014.952627 [Background reference on blood-brain barrier pharmacokinetics relevant to the CNS bioavailability discussion in this article.]